1031 related articles for article (PubMed ID: 28292272)
21. Prognostic factors for stage IV gastric cancer.
Baba H; Kuwabara K; Ishiguro T; Kumamoto K; Kumagai Y; Ishibashi K; Haga N; Ishida H
Int Surg; 2013; 98(2):181-7. PubMed ID: 23701157
[No Abstract] [Full Text] [Related]
22. Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
Kunisaki C; Makino H; Kimura J; Takagawa R; Kanazawa A; Ota M; Kosaka T; Ono HA; Akiyama H; Endo I
Oncology; 2015; 88(5):281-8. PubMed ID: 25591954
[TBL] [Abstract][Full Text] [Related]
23. Successful downstaging by S-1-based chemotherapy followed by surgical resections for gastric carcinoma with extensive distant lymph node metastasis - report of two cases and a review of cases with surgical resection after downstaging by S-1-based chemotherapy.
Yoshida I; Sakurai Y; Komori Y; Tonomura S; Masui T; Shoji M; Nakamura Y; Imazu H; Uyama I; Ochiai M
Hepatogastroenterology; 2005; 52(63):978-84. PubMed ID: 15966245
[TBL] [Abstract][Full Text] [Related]
24. Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma.
Hosoda K; Yamashita K; Katada N; Moriya H; Mieno H; Sakuramoto S; Kikuchi S; Watanabe M
Anticancer Res; 2015 Jan; 35(1):419-25. PubMed ID: 25550582
[TBL] [Abstract][Full Text] [Related]
25. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Kim SG; Hwang SH
World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
[TBL] [Abstract][Full Text] [Related]
26. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
Feng D; Leong M; Li T; Chen L; Li T
World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
[TBL] [Abstract][Full Text] [Related]
27. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
[TBL] [Abstract][Full Text] [Related]
28. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
29. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
Inoue T; Yachida S; Usuki H; Kimura T; Hagiike M; Okano K; Suzuki Y
Ann Surg Oncol; 2012 Sep; 19(9):2937-45. PubMed ID: 22466666
[TBL] [Abstract][Full Text] [Related]
30. [Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
Cui Y; Li J; Cao YH; Liu MY; Shi ZX; Gao TH
Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):195-200. PubMed ID: 28316218
[No Abstract] [Full Text] [Related]
31. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
Badgwell B; Blum M; Estrella J; Chiang YJ; Das P; Matamoros A; Fournier K; Mansfield P; Ajani J
J Am Coll Surg; 2015 Jul; 221(1):83-90. PubMed ID: 26002780
[TBL] [Abstract][Full Text] [Related]
32. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
34. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
Saito M; Kiyozaki H; Takata O; Suzuki K; Rikiyama T
World J Surg Oncol; 2014 Dec; 12():406. PubMed ID: 25551581
[TBL] [Abstract][Full Text] [Related]
35. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
36. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
[TBL] [Abstract][Full Text] [Related]
38. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Martin-Romano P; Sola JJ; Diaz-Gonzalez JA; Chopitea A; Iragorri Y; Martínez-Regueira F; Ponz-Sarvise M; Arbea L; Subtil JC; Cano D; Ceniceros L; Legaspi J; Hernandez JL; Rodríguez J
Br J Cancer; 2016 Sep; 115(6):655-63. PubMed ID: 27537382
[TBL] [Abstract][Full Text] [Related]
39. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
40. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
